Tenax Therapeutics, Inc.
TENXTenax Therapeutics, Inc. in brief
Tenax Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Chapel Hill, North Carolina, USA. Its market value was $86 M on 29 October 2026, which makes it the 19,330th largest listed company in the world and the 3,600th largest in the USA on this site. It employs about 14 people and Christopher Thomas Giordano is its chief executive. Its shares trade under the symbol TENX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Tenax Therapeutics, Inc.
Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. We employ a clinician-driven drug development approach, led by key opinion leaders and heart failure experts and informed by their clinical insights to precisely target disease pathophysiology. We are currently actively conducting the LEVEL and LEVEL-2 clinical trials to evaluate levosimendan as our prioritized product candidate and have deprioritized a Phase 3 clinical trial of imatinib, two drugs supported by promising evidence that they may significantly improve the lives of patients with pulmonary hypertension. Importantly, both levosimendan and imatinib have already been approved in other indications and prescribed around the world for more than 20 years, and we believe their mechanisms of action are uniquely suitable to target and treat pulmonary hypertension. We believe this derisked approach of using already-approved drugs that provide well-established safety profiles from millions of patients, combined with a development path led by preeminent cardiovascular and pulmonary hypertension experts, puts us in a strong position to deliver breakthrough cardiopulmonary therapies designed to improve patients’ functioning and quality of life.
From the company's annual report filed with the US SEC: read the report
Tenax Therapeutics, Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2008
- ✎Renamed Oxygen Biotherapeutics, Inc.Formerly Synthetic Blood International Inc.
- 2014
- ✎Renamed Tenax Therapeutics, Inc.Formerly Oxygen Biotherapeutics, Inc..
Events of Tenax Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,672 (Jan 2020) · #4,335 (Jan 2021) · #5,361 (Jan 2022) · #5,759 (Dec 2022) · #5,533 (Jul 2023) · #4,630 (Jan 2024) · #2,063 (Mar 2026) · #3,626 (Aug 2026) · #3,595 (Oct 2026) · #3,603 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.9×
- Free cash flow yield
- -13.3%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -54.2%
- Liabilities / assets
- 6.9%
- Revenue growth
- -68.8%
- R&D / revenue
- 13320.0%
- Profit per employee
- $-3.8 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-56M | $-53M | — |
| Dec 2024 | — | — | $-19M | $-18M | — |
| Dec 2023 | — | — | $-8M | $-8M | — |
| Dec 2022 | — | — | $11M | $11M | — |
| Dec 2021 | — | — | $-33M | $-32M | — |
| Dec 2020 | — | — | $10M | $-10M | — |
| Dec 2019 | — | — | $-9M | $-8M | — |
| Dec 2018 | — | — | $-7M | $-14M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-36M | — | — | $-1.34 | — |
| Dec 2024 | $-15M | — | — | $-1.15 | — |
| Dec 2023 | $-6M | — | — | $-31.04 | — |
| Dec 2022 | $-11M | $0M | $-11M | — | — |
| Dec 2021 | $-11M | $0M | $-11M | $-1.58 | — |
| Dec 2020 | $-9M | $0M | $-9M | $-0.95 | — |
| Dec 2019 | $-8M | $0M | $-8M | $-1.35 | — |
| Dec 2018 | $-6M | $0M | $-6M | $-9.04 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-17M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations
- Oct 8, 20268-KCurrent reportOther events
- Sep 9, 20268-KCurrent reportRegulation FD disclosure
- Aug 10, 20268-KCurrent reportOther events
- Jul 31, 202610-QQuarterly report · period to Jun 2026
- Jul 31, 20268-KCurrent reportResults of operations
- Jul 2, 20268-KCurrent reportOther events
- Jun 30, 20268-KCurrent reportMaterial agreement
- Jun 29, 20268-KCurrent reportDirectors or officers changed · Other events
- Jun 4, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
Official filings of Tenax Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-56 M
- Net income
- $-53 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $104 M
- Total liabilities
- $7 M
- Total equity
- $97 M
As of December-2025
Top 100 institutional investors in Tenax Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | ADAR1 Capital Management, LLC | 6,524,151 | +6,303,689 (+2859.31%) | 14.33% | $12 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 2,805,496 | +1,077,508 (+62.36%) | 6.16% | $5 M | Nov 13, 2026 |
| 3 | Vivo Capital, LLC | 2,500,000 | 0 (0.00%) | 5.49% | $5 M | Nov 13, 2026 |
| 4 | Sphera Funds Management LTD. | 2,315,696 | +2,195,496 (+1826.54%) | 5.09% | $4 M | Nov 16, 2026 |
| 5 | Marshall Wace, LLP | 1,779,564 | +1,193,986 (+203.90%) | 3.91% | $3 M | Nov 13, 2026 |
| 6 | Millennium Management LLC | 1,362,730 | +486,500 (+55.52%) | 2.99% | $3 M | Nov 16, 2026 |
| 7 | AQR Capital Management LLC | 1,252,703 | New | 2.75% | $2 M | Nov 16, 2026 |
| 8 | Vanguard Capital Management LLC | 1,131,973 | -15,148 (-1.32%) | 2.49% | $2 M | Nov 13, 2026 |
| 9 | Morgan Stanley | 942,937 | +510,717 (+118.16%) | 2.07% | $2 M | Nov 13, 2026 |
| 10 | Geode Capital Management, LLC | 864,596 | +225,059 (+35.19%) | 1.90% | $2 M | Nov 6, 2026 |
| 11 | Jane Street Group, LLC | 689,312 | +422,656 (+158.50%) | 1.51% | $1 M | Nov 12, 2026 |
| 12 | Goldman Sachs Group Inc | 627,023 | +352,077 (+128.05%) | 1.38% | $1 M | Nov 16, 2026 |
| 13 | Stonepine Capital Management, LLC | 588,000 | -72,000 (-10.91%) | 1.29% | $1 M | Nov 13, 2026 |
| 14 | Braidwell LP | 584,412 | 0 (0.00%) | 1.28% | $1 M | Nov 16, 2026 |
| 15 | Wellington Management Group LLP | 555,995 | +460,482 (+482.11%) | 1.22% | $1 M | Nov 16, 2026 |
| 16 | State Street Corp | 535,410 | +24,596 (+4.82%) | 1.18% | $1 M | Nov 12, 2026 |
| 17 | FMR LLC | 533,217 | -3,409,156 (-86.47%) | 1.17% | $1 M | Nov 10, 2026 |
| 18 | Caitong International Asset Management Co., Ltd | 489,906 | +489,756 (+326504.00%) | 1.08% | $1 M | Oct 29, 2026 |
| 19 | Susquehanna International Group, LLP | 428,063 | +138,899 (+48.03%) | 0.94% | $1 M | Nov 16, 2026 |
| 20 | Adage Capital Partners GP, L.L.C. | 409,733 | -130,393 (-24.14%) | 0.90% | $1 M | Nov 16, 2026 |
| 21 | Balyasny Asset Management L.P. | 369,587 | New | 0.81% | $1 M | Nov 16, 2026 |
| 22 | Qube Research & Technologies Ltd | 280,621 | -149,272 (-34.72%) | 0.62% | $1 M | Nov 13, 2026 |
| 23 | UBS Group AG | 274,223 | +176,080 (+179.41%) | 0.60% | $1 M | Nov 10, 2026 |
| 24 | Prudential Financial Inc | 249,695 | New | 0.55% | $0 M | Nov 16, 2026 |
| 25 | Vanguard Portfolio Management LLC | 247,776 | +78,935 (+46.75%) | 0.54% | $0 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Quadrature Capital Ltd | 238,886 | New | 0.52% | $0 M | Nov 13, 2026 |
| 27 | Northern Trust Corp | 234,818 | +35,684 (+17.92%) | 0.52% | $0 M | Nov 16, 2026 |
| 28 | Ensign Peak Advisors, Inc | 234,205 | +57,316 (+32.40%) | 0.51% | $0 M | Nov 12, 2026 |
| 29 | Nuveen, LLC | 215,359 | +54,172 (+33.61%) | 0.47% | $0 M | Nov 10, 2026 |
| 30 | Vanguard Fiduciary Trust Co | 212,850 | +55,808 (+35.54%) | 0.47% | $0 M | Nov 13, 2026 |
| 31 | Walleye Capital LLC | 204,144 | +98,907 (+93.99%) | 0.45% | $0 M | Nov 13, 2026 |
| 32 | Citigroup Inc | 175,348 | +163,725 (+1408.63%) | 0.39% | $0 M | Nov 4, 2026 |
| 33 | LMR Partners LLP | 150,489 | New | 0.33% | $0 M | Nov 16, 2026 |
| 34 | Ikarian Capital, LLC | 136,648 | -650,952 (-82.65%) | 0.30% | $0 M | Nov 16, 2026 |
| 35 | Barclays PLC | 124,205 | +116,151 (+1442.15%) | 0.27% | $0 M | Nov 6, 2026 |
| 36 | Jones Hill Capital LP | 122,169 | New | 0.27% | $0 M | Nov 13, 2026 |
| 37 | Engineers Gate Manager LP | 99,996 | New | 0.22% | $0 M | Nov 16, 2026 |
| 38 | Caption Management, LLC | 93,005 | -161,995 (-63.53%) | 0.20% | $0 M | Nov 16, 2026 |
| 39 | Charles Schwab Investment Management Inc | 89,743 | +28,569 (+46.70%) | 0.20% | $0 M | Nov 16, 2026 |
| 40 | Bank of New York Mellon Corp | 84,079 | -241,217 (-74.15%) | 0.18% | $0 M | Nov 5, 2026 |
| 41 | Dimensional Fund Advisors LP | 74,577 | -178,941 (-70.58%) | 0.16% | $0 M | Nov 4, 2026 |
| 42 | Gsa Capital Partners LLP | 72,503 | New | 0.16% | $0 M | Nov 16, 2026 |
| 43 | Verdad Advisers, LP | 62,127 | -61,047 (-49.56%) | 0.14% | $0 M | Nov 16, 2026 |
| 44 | Axq Capital, LP | 61,424 | New | 0.13% | $0 M | Nov 12, 2026 |
| 45 | Bridgeway Capital Management, LLC | 59,900 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 46 | Rangeley Capital, LLC | 55,000 | New | 0.12% | $0 M | Nov 16, 2026 |
| 47 | State of Alaska, Department of Revenue | 50,000 | New | 0.11% | $0 M | Oct 15, 2026 |
| 48 | Alps Advisors Inc | 49,225 | +22,301 (+82.83%) | 0.11% | $0 M | Nov 3, 2026 |
| 49 | Panagora Asset Management Inc | 44,280 | -111,782 (-71.63%) | 0.10% | $0 M | Nov 12, 2026 |
| 50 | XTX Topco Ltd | 40,919 | -72,848 (-64.03%) | 0.09% | $0 M | Nov 16, 2026 |
| 51 | Creek Drive Management Group LLC | 38,000 | -36,000 (-48.65%) | 0.08% | $0 M | Nov 10, 2026 |
| 52 | Deutsche Bank AG\ | 35,381 | +10,824 (+44.08%) | 0.08% | $0 M | Nov 6, 2026 |
| 53 | Simplex Trading, LLC | 32,403 | New | 0.07% | $0 M | Nov 4, 2026 |
| 54 | Rhumbline Advisers | 30,617 | -674 (-2.15%) | 0.07% | $0 M | Nov 10, 2026 |
| 55 | Bank Of America Corp /de/ | 30,189 | -106,239 (-77.87%) | 0.07% | $0 M | Nov 16, 2026 |
| 56 | Jpmorgan Chase & Co | 28,208 | +17,697 (+168.37%) | 0.06% | $0 M | Nov 12, 2026 |
| 57 | Boothbay Fund Management, LLC | 27,464 | -283,623 (-91.17%) | 0.06% | $0 M | Nov 16, 2026 |
| 58 | BVF Inc/il | 25,000 | -314,549 (-92.64%) | 0.05% | $0 M | Nov 16, 2026 |
| 59 | Wells Fargo & Company/mn | 24,139 | +3,055 (+14.49%) | 0.05% | $0 M | Nov 16, 2026 |
| 60 | Two Sigma Investments, LP | 24,027 | -329,363 (-93.20%) | 0.05% | $0 M | Nov 16, 2026 |
| 61 | Russell Investments Group, Ltd. | 22,667 | +20,616 (+1005.17%) | 0.05% | $0 M | Nov 6, 2026 |
| 62 | Vanguard Personalized Indexing Management, LLC | 21,144 | New | 0.05% | $0 M | Nov 16, 2026 |
| 63 | Price T Rowe Associates Inc /MD/ | 20,670 | -586,990 (-96.60%) | 0.05% | $0 M | Nov 16, 2026 |
| 64 | Alliancebernstein L.P. | 19,900 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 65 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 17,481 | +5,937 (+51.43%) | 0.04% | $0 M | Nov 16, 2026 |
| 66 | WINTON GROUP Ltd | 16,900 | New | 0.04% | $0 M | Nov 12, 2026 |
| 67 | Gabelli Funds LLC | 15,000 | New | 0.03% | $0 M | Nov 12, 2026 |
| 68 | Invesco Ltd. | 14,301 | +1,205 (+9.20%) | 0.03% | $0 M | Nov 12, 2026 |
| 69 | Verition Fund Management LLC | 13,589 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 70 | BNP Paribas Financial Markets | 12,510 | -35,325 (-73.85%) | 0.03% | $0 M | Nov 12, 2026 |
| 71 | Corient Private Wealth LP | 12,388 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 72 | Letko, Brosseau & Associates Inc | 10,650 | 0 (0.00%) | 0.02% | $0 M | Nov 6, 2026 |
| 73 | Callan Family Office, LLC | 10,453 | New | 0.02% | $0 M | Nov 13, 2026 |
| 74 | Mendel Money Management | 10,300 | New | 0.02% | $0 M | Nov 2, 2026 |
| 75 | Centiva Capital, LP | 10,211 | New | 0.02% | $0 M | Nov 13, 2026 |
| 76 | SEI Investments Co | 10,110 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 77 | Vanguard Global Advisers, LLC | 10,015 | -2,095 (-17.30%) | 0.02% | $0 M | Nov 13, 2026 |
| 78 | IFG Advisors, LLC | 10,000 | New | 0.02% | $0 M | Oct 15, 2026 |
| 79 | Global Retirement Partners, LLC | 9,335 | New | 0.02% | $0 M | Nov 10, 2026 |
| 80 | New York State Common Retirement Fund | 8,800 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 81 | Pinnacle Wealth Planning Services, Inc. | 8,103 | New | 0.02% | $0 M | Oct 27, 2026 |
| 82 | Police & Firemen's Retirement System of New Jersey | 7,425 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 83 | PNC Financial Services Group, Inc. | 6,066 | New | 0.01% | $0 M | Nov 6, 2026 |
| 84 | Tower Research Capital LLC (TRC) | 5,927 | +3,619 (+156.80%) | 0.01% | $0 M | Nov 16, 2026 |
| 85 | Strs Ohio | 4,900 | 0 (0.00%) | 0.01% | $0 M | Oct 30, 2026 |
| 86 | Federated Hermes, Inc. | 4,579 | New | 0.01% | $0 M | Nov 12, 2026 |
| 87 | GAMMA Investing LLC | 2,591 | New | 0.01% | $0 M | Oct 8, 2026 |
| 88 | Legal & General Group Plc | 2,442 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 89 | Bradley & Co. Private Wealth Management, LLC | 2,325 | New | 0.01% | $0 M | Oct 23, 2026 |
| 90 | Ameritas Investment Partners, Inc. | 2,285 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 91 | Jones Financial Companies Lllp | 2,090 | +2,089 (+208900.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 92 | Royal Bank Of Canada | 1,982 | +1,206 (+155.41%) | 0.00% | $0 M | Nov 16, 2026 |
| 93 | EverSource Wealth Advisors, LLC | 1,877 | New | 0.00% | $0 M | Nov 4, 2026 |
| 94 | Parkside Financial Bank & Trust | 1,520 | New | 0.00% | $0 M | Oct 27, 2026 |
| 95 | Sterling Capital Management LLC | 712 | +205 (+40.43%) | 0.00% | $0 M | Oct 22, 2026 |
| 96 | Arax Advisory Partners | 407 | New | 0.00% | $0 M | Nov 12, 2026 |
| 97 | SBI Securities Co., Ltd. | 388 | +331 (+580.70%) | 0.00% | $0 M | Oct 22, 2026 |
| 98 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 378 | New | 0.00% | $0 M | Nov 16, 2026 |
| 99 | California State Teachers Retirement System | 347 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 100 | Fortitude Family Office, LLC | 343 | New | 0.00% | $0 M | Oct 14, 2026 |
Mutual funds holding Tenax Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 852,259 | $12 M | 17.4% | <0.01% | +339% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 648,782 | $9 M | 13.3% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 445,976 | $6 M | 9.1% | 0.05% | −82% | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 445,100 | $6 M | 9.1% | 0.28% | +38% | Jul 31, 2026 |
| 🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC | 432,200 | $6 M | 8.8% | 0.15% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Discovery FundFidelity Management & Research Company LLC | 335,016 | $5 M | 6.9% | 0.20% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Small Cap Discovery FundFidelity Management & Research Company LLC | 299,100 | $4 M | 6.1% | 0.21% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 277,850 | $4 M | 5.7% | <0.01% | +333% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC | 282,400 | $4 M | 5.8% | 0.25% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 275,703 | $4 M | 5.6% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 228,271 | $3 M | 4.7% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 BNY Mellon Small/Mid Cap Growth FundBNY Mellon Investment Funds I | 125,362 | $2 M | 2.6% | 0.21% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 83,907 | $1 M | 1.7% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 68,684 | $1 M | 1.4% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC | 76,941 | $1 M | 1.6% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 61,174 | $1 M | 1.3% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 57,630 | $1 M | 1.2% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 53,228 | $1 M | 1.1% | <0.01% | +127% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 46,654 | $1 M | 0.95% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 45,100 | $1 M | 0.92% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 43,036 | $1 M | 0.88% | 0.08% | −72% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 35,209 | $1 M | 0.72% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 PGIM Quant Solutions Large-Cap Core FundPGIM INVESTMENTS LLC | 35,100 | $0 M | 0.72% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 34,147 | $0 M | 0.70% | <0.01% | +169% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 33,669 | $0 M | 0.69% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 27,186 | $0 M | 0.56% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 27,926 | $0 M | 0.57% | <0.01% | +103% | Jul 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 27,208 | $0 M | 0.56% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 28,375 | $0 M | 0.58% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 18,400 | $0 M | 0.38% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 12,955 | $0 M | 0.26% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 12,618 | $0 M | 0.26% | 0.16% | — | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 11,936 | $0 M | 0.24% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 11,967 | $0 M | 0.24% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 9,950 | $0 M | 0.20% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 9,950 | $0 M | 0.20% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 11,937 | $0 M | 0.24% | <0.01% | +482% | May 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 9,723 | $0 M | 0.20% | 0.06% | +709% | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 8,857 | $0 M | 0.18% | 0.07% | +952% | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 9,046 | $0 M | 0.18% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 8,471 | $0 M | 0.17% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 BNY Mellon Small Cap Multi-Strategy FundBNY Mellon Investment Adviser, Inc. | 10,321 | $0 M | 0.21% | 0.09% | new | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 7,400 | $0 M | 0.15% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 8,940 | $0 M | 0.18% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,907 | $0 M | 0.18% | <0.01% | −10% | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 7,153 | $0 M | 0.15% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 6,030 | $0 M | 0.12% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 5,649 | $0 M | 0.12% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 5,569 | $0 M | 0.11% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 5,553 | $0 M | 0.11% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 5,427 | $0 M | 0.11% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 5,403 | $0 M | 0.11% | <0.01% | +140% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 5,076 | $0 M | 0.10% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 4,385 | $0 M | 0.09% | <0.01% | +55% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 4,364 | $0 M | 0.09% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 3,954 | $0 M | 0.08% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 3,885 | $0 M | 0.08% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 3,797 | $0 M | 0.08% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 3,371 | $0 M | 0.07% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 3,051 | $0 M | 0.06% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 3,160 | $0 M | 0.06% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 3,030 | $0 M | 0.06% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 2,948 | $0 M | 0.06% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 2,751 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 2,622 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 2,603 | $0 M | 0.05% | <0.01% | +174% | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 2,345 | $0 M | 0.05% | <0.01% | +43% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 2,285 | $0 M | 0.05% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,223 | $0 M | 0.05% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 2,064 | $0 M | 0.04% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 2,009 | $0 M | 0.04% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,811 | $0 M | 0.04% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,643 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,180 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 1,171 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 1,076 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,099 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 1,090 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 880 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 800 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 636 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 335 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 82 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Tenax Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +331,979 | $1.659 | $551 K | 7.45 M | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +254,342 | $1.595 | $406 K | 7.12 M | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +336,528 | $1.507 | $507 K | 6.86 M | Form 4 |
| filed | Declan DooganDirector | Buy | +53,000 | $1.920 | $102 K | 55,274 | Form 4 |
| filed | Christopher Thomas GiordanoCEO, Director | Buy | +4,850 | $1.820 | $9 K | 22,174 | Form 4 |
| filed | Thomas R. Staab IIChief Financial Officer | Buy | +5,675 | $1.940 | $11 K | 15,675 | Form 4 |
| filed | Christopher Thomas GiordanoCEO, Director | Buy | +6,000 | $1.880 | $11 K | 17,324 | Form 4 |
| filed | ADAR1 Capital Management, LLC10% owner | Buyindirect | +900,000 | $1.780 | $1.6 M | 6.52 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Tenax Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-06-20 17:39 UTC, code LUDP, resumed 17:44 UTC
Fails to deliver
- : 3,230 shares at $1.88
- : 292 shares at $1.83
- : 2,180 shares at $1.91
- : 350 shares at $1.93
- : 1,827 shares at $1.98
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Tenax Therapeutics, Inc. scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.9×Price to book 0.9× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-13.3%Free cash flow is -13.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.34 vs -1.15Diluted EPS -1.34 in fiscal 2025 against -1.15 the year before (report's currency).
- ✗Net income higher than five years earlier-$53 M-$53 M in fiscal 2025 against -$10 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$53 MNet income -$53 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-55.6%-55.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities14.6×Current ratio 14.56 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year156.8%Diluted shares up 156.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Tenax Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0—— | 0—— | — | — | — | — | — | — | — | 0—— | |
| Cost of revenue | — | — | — | — | — | — | — | — | — | 0—— | |
| Gross profit | — | — | — | — | — | — | — | — | — | 0—— | |
| Research and development | 33+157%— | 13+294%— | 3.2r3.2−40.0%— | 5.4−78.6%— | 25+451%— | 4.6+31.4%— | 3.5+180%— | 1.2−64.9%— | 3.5−73.2%— | 13—— | |
| Selling, general and administrative | — | — | — | — | 7.6+42.8%— | 5.3+4.4%— | 5.1−10.1%— | 5.7−0.4%— | 5.7−9.1%— | 6.2—— | |
| General and administrative | 24+249%— | 6.8+35.6%— | 5.0r5.0−11.8%— | 5.7−25.1%— | 7.6—— | — | — | — | — | — | |
| Operating expenses | 56+189%— | 19+137%— | 8.2r8.2−25.5%— | 11−66.2%— | 33+232%— | 9.9+15.3%— | 8.6+24.1%— | 6.9−25.1%— | 9.2−82.5%— | 53—— | |
| Operating income | −56—— | −19—— | −8.2r8.2−174%— | 11r−11—— | −33r33−432%— | 9.9r−9.9—— | −8.6—— | −6.9—— | −9.2—— | −53—— | |
| Interest expense and finance costs | 0−100%— | 0.0−4.2%— | 0.0r0.0+440%— | 0.0+368%— | 0.0−41.7%— | 0.0—— | 0—— | — | — | 0—— | |
| Net interest income | — | — | — | — | 0.0−41.7%— | 0.0—— | — | — | — | — | |
| Other non-operating income (expense) | −0.0−3400%— | 0.0−98.4%— | 0.1r−0.5—— | −0.0—— | — | 0.0−88.7%— | 0.2+102%— | 0.1−78.2%— | 0.4−52.1%— | 0.8—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | −8.0—— | |
| Net income including minority interests | −53—— | −18—— | −7.7r−7.7—— | −11—— | −32r32−430%— | 9.9—— | — | — | — | — | |
| Net income attributable to shareholders | −53—— | −18—— | −7.7r7.7−170%— | 11r−11—— | −32—— | −9.9—— | −8.4—— | −14—— | −8.8—— | −44—— | |
| Earnings per share, basic | -1.34—— | -1.15—— | -31.04—— | — | -1.58—— | -0.95r-1.33—— | -1.35—— | -9.04—— | -6.27—— | -31.24r-1.56—— | |
| Earnings per share, diluted | -1.34—— | -1.15—— | -31.04—— | — | -1.58—— | -0.95r-1.33—— | -1.35—— | -9.04—— | -6.27—— | -31.24r-1.56—— | |
| Shares, weighted average (basic) | 39+157%— | 15+6047%— | 0.2—— | — | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 39+157%— | 15+6047%— | 0.2—— | — | 21+98.5%— | 10r7.4+67.3%— | 6.2+296%— | 1.6+10.9%— | 1.4+0.3%— | 1.4r28—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 98+2.8%93.6% | 95+868%98.2% | 9.8+361%83.9% | 2.1−62.0%62.4% | 5.6−10.7%93.2% | 6.3+27.4%91.0% | 4.9−60.3%77.1% | 12+671%92.7% | 1.6−83.9%16.2% | 10.0—42.8% | |
| Short-term investments | — | — | — | — | 0−100%0.0% | 0.5−6.3%6.7% | 0.5−0.2%7.8% | 0.5−91.9%3.7% | 6.1+86.4%61.9% | 3.3—14.1% | |
| Receivables | — | — | — | — | — | — | — | 0−100%0.0% | 0.1−30.9%0.5% | 0.1—0.3% | |
| Other current assets | 1.0+1492%1.0% | 0.1r0.1−74.6%0.1% | 0.3r0.3−27.1%2.2% | 0.3—10.2% | 0—0.0% | — | — | — | — | — | |
| Current assets | 104+7.8%100% | 97+728%100% | 12r12+264%100.0% | 3.2−43.6%94.2% | 5.7−16.3%94.9% | 6.8+9.9%98.9% | 6.2−53.6%97.1% | 13+65.2%99.9% | 8.1−40.8%81.5% | 14—58.4% | |
| Property, plant and equipment | — | — | 0−100%0.0% | 0.0+1.1%0.2% | 0.0+19.0%0.1% | 0.0−8.9%0.1% | 0.0−23.1%0.1% | 0.0−14.3%0.1% | 0.0−47.9%0.1% | 0.0—0.1% | |
| Right-of-use (leased) assets | — | — | 0−100%0.0% | 0.2−37.6%5.3% | 0.3+389%4.8% | 0.1−65.3%0.9% | 0.2—2.7% | 0—0.0% | — | — | |
| Goodwill | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total assets | 104+7.8%100% | 97+727%100% | 12r12+243%100% | 3.4−43.2%100% | 6.0−12.8%100% | 6.9+7.9%100% | 6.4−52.3%100% | 13+34.8%100% | 9.9−57.6%100% | 23—100% | |
| Accounts payable | 6.0+91.4%5.8% | 3.2+52.3%3.3% | 2.1r2.1+362%17.7% | 0.4−47.8%13.2% | 0.9+13.4%14.3% | 0.8−54.4%11.0% | 1.7+122%26.1% | 0.7+22.5%5.6% | 0.6−15.9%6.2% | 0.7—3.1% | |
| Current liabilities | 7.2+52.5%6.9% | 4.7+30.8%4.9% | 3.6r3.6+94.1%30.7% | 1.8+18.1%54.3% | 1.6−26.2%26.1% | 2.1−16.3%30.8% | 2.5+61.7%39.8% | 1.6+55.2%11.7% | 1.0−83.7%10.2% | 6.2—26.6% | |
| Lease liabilities (non-current) | — | — | 0−100%0.0% | 0.1−65.0%1.9% | 0.2—3.1% | 0−100%0.0% | 0.1—0.9% | 0—0.0% | — | — | |
| Non-current liabilities | — | — | 0−100%0.0% | 0.1−65.0%1.9% | 0.2+47.9%3.1% | 0.1+106%1.8% | 0.1—0.9% | — | — | — | |
| Total liabilities | 7.2+52.5%6.9% | 4.7+30.8%4.9% | 3.6r3.6+87.6%30.7% | 1.9+9.4%56.2% | 1.7−22.1%29.2% | 2.2−13.5%32.7% | 2.6+65.6%40.7% | 1.6+55.2%11.7% | 1.0−83.7%10.2% | 6.2—26.6% | |
| Retained earnings | −367—−353% | −315—−326% | −297r−297—−2544% | −290—−8504% | −278—−4648% | −246—−3582% | −236—−3710% | −228—−1708% | −213—−2159% | −205—−877% | |
| Shareholders' equity | 97+5.5%93.1% | 92+1036%95.1% | 8.1r8.1+442%69.3% | 1.5r1.5−64.8%43.9% | 4.2−8.2%70.8% | 4.6+22.6%67.3% | 3.8−68.0%59.3% | 12+32.5%88.3% | 8.9−48.2%89.8% | 17—73.4% | |
| Total liabilities and equity | 104+7.8%100% | 97+727%100% | 12r12+243%100% | 3.4−43.2%100% | 6.0−12.8%100% | 6.9+7.9%100% | 6.4−52.3%100% | 13+34.8%100% | 9.9−57.6%100% | 23—100% | |
| Shares outstanding | 9.3+172%— | 3.4+1047%— | 0.3+941%— | 0.0r2.3−97.7%— | 1.3r25−90.0%— | 13+87.2%— | 6.7+77.8%— | 3.8+169%— | 1.4+0.4%— | 1.4r28—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 0−100%— | 0.0r0.0+55.6%— | 0.0+25.0%— | 0.0+1.0%— | 0.0−18.7%— | 0.0−44.4%— | 0.0−33.8%— | 0.0−28.1%— | 0.0—— | |
| Share-based compensation | 19+1603%— | 1.1+489%— | 0.2—— | — | — | — | 0−100%— | 0.2+139%— | 0.1+7394%— | 0.0—— | |
| Cash from operating activities | −36—— | −15—— | −5.9r−5.9—— | −11r−12—— | −11—— | −9.3—— | −7.6—— | −5.5—— | −12—— | −16—— | |
| Capital expenditure | — | — | — | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | |
| Intangible assets bought | — | — | — | — | — | — | — | — | — | 0—— | |
| Cash from investing activities | — | 0−100%— | 0.0r0.0—— | −0.0−101%— | 0.5+2151%— | 0.0—— | −0.0−100%— | 7.4+96.2%— | 3.7−83.1%— | 22—— | |
| Debt repaid | — | — | — | — | −0.2—— | — | — | — | — | — | |
| Shares issued | — | — | — | — | — | 8.7—— | 0—— | — | — | — | |
| Cash from financing activities | 39−61.4%— | 100+636%— | 14r14+71.1%— | 7.9r8.6−18.6%— | 9.7−8.1%— | 11+10881%— | 0.1−98.9%— | 8.9—— | 0—— | 0—— | |
| Change in cash | — | — | — | — | — | 1.3—— | −7.5−169%— | 11—— | −8.4−232%— | 6.3—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | — | — | — | — | — | |
| Research and development | 47+75.8%— | 12+16.8%— | 13+110%— | 12+103%— | 11*+129%— | 10+232%— | 6.1+163%— | 5.7+112%— | 4.6r4.6*+170%— | 3.1r3.1—— | 2.3r2.3—— | 2.7r2.7—— | 1.7r1.7*—— | |
| Selling, general and administrative | — | 5.7−12.6%— | 5.9+4.6%— | — | — | 6.5—— | 5.7—— | — | — | — | — | — | — | |
| General and administrative | — | — | — | 5.0−11.0%— | 5.9*+119%— | 6.5+330%— | 5.7+322%— | 5.7+359%— | 2.7r2.7*+64.5%— | 1.5r1.5—— | 1.3r1.3—— | 1.2r1.2—— | 1.6r1.6*—— | |
| Operating expenses | 70+47.2%— | 18+5.5%— | 19+59.3%— | 17+46.2%— | 16*+125%— | 17+264%— | 12+221%— | 11+190%— | 7.3r7.3*+118%— | 4.6r4.6—— | 3.7r3.7—— | 3.9r3.9—— | 3.3r3.3*—— | |
| Operating income | −70—— | −18—— | −19—— | −17—— | −16*—— | −17—— | −12—— | −11—— | −7.3r−32*—— | −4.6r4.6—— | −3.7r3.7—— | −3.9r−3.9—— | −13r3.3*—— | |
| Interest expense and finance costs | — | — | — | — | 0*—— | 0*−100%— | 0*−100%— | 0−100%— | — | 0.0r0.0—— | 0.0r0.0—— | 0.0r0.0—— | 0.0r0.0*—— | |
| Other non-operating income (expense) | −0.0—— | −0.0—— | 0—— | −0.0—— | −0.0*−644%— | −0.0—— | −0.0−1000%— | 0—— | 0.0*−98.7%— | 0—— | 0.0r−0.0—— | −0.1—— | 0.1r−0.5*—— | |
| Net income including minority interests | −66—— | −17*—— | −18*—— | −16—— | −16*—— | −16*—— | −11*—— | −10—— | −6.3r−6.3*—— | −4.0r−19*—— | −3.6r11*—— | −3.8r−3.8—— | −3.2r−3.2*—— | |
| Net income attributable to shareholders | −66—— | −17—— | −18—— | −16—— | −16*—— | −16—— | −11—— | −10—— | −6.3r−29*—— | −4.0r4.0—— | −3.6r3.6—— | −3.8r3.8—— | −12r3.2*—— | |
| Earnings per share, basic | — | -0.31—— | -0.35—— | -0.35—— | — | -0.40—— | -0.27—— | -0.28—— | — | -0.19—— | -1.83—— | -3.12—— | — | |
| Earnings per share, diluted | — | -0.31—— | -0.35—— | -0.35—— | — | -0.40—— | -0.27—— | -0.28—— | — | -0.19—— | -1.83—— | -3.12—— | — | |
| Shares, weighted average (basic) | 53+34.5%— | 53+34.5%— | 51+28.5%— | 45+23.6%— | — | 40+87.8%— | 40+1921%— | 37+2901%— | — | 21—— | 2.0—— | 1.2—— | — | |
| Shares, weighted average (diluted) | 53+34.5%— | 53+34.5%— | 51+28.5%— | 45+23.6%— | — | 40+87.8%— | 40+1921%— | 37+2901%— | — | 21—— | 2.0—— | 1.2—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 114—97.2% | 114+14.4%97.2% | 118+11.8%97.0% | 119+6.6%96.4% | 98+2.8%93.6% | 99+1.1%96.7% | 106+1024%99.7% | 111+788%99.4% | 95+868%98.2% | 98r98—98.5% | 9.4r9.4—88.4% | 13r13—86.8% | 9.8—83.9% | |
| Other current assets | 0.1—0.1% | 0.1−96.9%0.1% | 0.3−31.1%0.2% | 0.1+21.6%0.1% | 1.0+1492%1.0% | 3.4+10058%3.3% | 0.4+686%0.4% | 0.1+32.1%0.1% | 0.1r0.1−74.6%0.1% | 0.0—0.0% | 0.1—0.5% | 0.1—0.5% | 0.3r0.3—2.2% | |
| Current assets | 117—100% | 117+13.8%100% | 122+14.9%100% | 123+9.9%100% | 104+7.8%100% | 103+3.0%100% | 106+897%100% | 112+675%100% | 97+728%100% | 100—100.0% | 11—100.0% | 14—100.0% | 12r12—100.0% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total assets | 117—100% | 117+13.8%100% | 122+14.9%100% | 123+9.9%100% | 104+7.8%100% | 103+3.0%100% | 106+897%100% | 112+675%100% | 97+727%100% | 100—100% | 11—100% | 14—100% | 12r12—100% | |
| Accounts payable | 6.6—5.6% | 6.6+17.2%5.6% | 6.8+1109%5.6% | 6.3+245%5.2% | 6.0+91.4%5.8% | 5.6+254%5.5% | 0.6−35.4%0.5% | 1.8+70.1%1.6% | 3.2+52.3%3.3% | 1.6—1.6% | 0.9—8.2% | 1.1—7.5% | 2.1r2.1—17.7% | |
| Customer deposits | — | — | — | — | — | — | — | — | — | 98—97.8% | 8.9—83.8% | 12—80.2% | — | |
| Current liabilities | 8.4—7.1% | 8.4+26.6%7.1% | 8.1+219%6.6% | 8.5+207%6.9% | 7.2+52.5%6.9% | 6.6+158%6.4% | 2.5+45.2%2.4% | 2.8+36.3%2.5% | 4.7+30.8%4.9% | 2.6—2.6% | 1.7—16.4% | 2.0—14.0% | 3.6r3.6—30.7% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Non-current liabilities | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total liabilities | 8.4—7.1% | 8.4+26.6%7.1% | 8.1+219%6.6% | 8.5+207%6.9% | 7.2+52.5%6.9% | 6.6+158%6.4% | 2.5+45.2%2.4% | 2.8+36.3%2.5% | 4.7+30.8%4.9% | 2.6—2.6% | 1.7—16.4% | 2.0—14.0% | 3.6r3.6—30.7% | |
| Retained earnings | −418—−357% | −418—−357% | −401—−330% | −383—−311% | −367—−353% | −352—−342% | −336—−318% | −325—−290% | −315—−326% | −309—−309% | −305—−2869% | −301—−2082% | −297r−297—−2544% | |
| Shareholders' equity | 109—92.9% | 109+12.9%92.9% | 114+9.9%93.4% | 115+4.9%93.1% | 97+5.5%93.1% | 96−1.0%93.6% | 103+1064%97.6% | 109+779%97.5% | 92+1036%95.1% | 97r97—97.4% | 8.9r8.9—83.6% | 12r12—86.0% | 8.1r8.1—69.3% | |
| Total liabilities and equity | 117—100% | 117+13.8%100% | 122+14.9%100% | 123+9.9%100% | 104+7.8%100% | 103+3.0%100% | 106+897%100% | 112+675%100% | 97+727%100% | 100—100% | 11—100% | 14—100% | 12r12—100% | |
| Shares outstanding | 46—— | 46+671%— | 32+670%— | 24+511%— | 9.3+172%— | 5.9+73.3%— | 4.1+112%— | 4.0+103%— | 3.4+1047%— | 3.4—— | 2.0—— | 2.0—— | 0.3—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 0*−100%— | 0*—— | 0*—— | 0—— | 0.0r0.0*—— | |
| Share-based compensation | 13−15.1%— | 2.4−56.4%— | 2.8−37.8%— | 2.8−31.5%— | 4.8*+394%— | 5.5+61011%— | 4.5+44900%— | 4.1+3381%— | 1.0*—— | 0.0—— | 0.0—— | 0.1—— | — | |
| Cash from operating activities | −49—— | −12*—— | −14*—— | −9.3—— | −13*—— | −9.2*—— | −6.3*—— | −7.0—— | −3.5r−3.5*—— | −3.1r−3.1*—— | −3.0r−3.0*—— | −5.2—— | −1.2r−1.2*—— | |
| Cash from investing activities | — | — | — | — | — | 0*—— | 0*—— | 0—— | 0*−100%— | 0*—— | 0*—— | 0—— | 0.0r0*—— | |
| Cash from financing activities | 64+136%— | 8.2*+169%— | 13*+4710%— | 30+29.4%— | 12*+17230%— | 3.1*−96.7%— | 0.3*—— | 24+197%— | 0.1r0.1*—— | 92r92*—— | −0.1r−0.1*—— | 7.9r7.9—— | −0.2r−0.2*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Tenax Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Christopher T. Giordano | $8.1 M | $21.7 M | $1.9 M | $1 |
| 2024Christopher Thomas Giordano | $7.4 M | $7.7 M | $1.7 M | $0 |
| 2023Christopher Thomas Giordano | $645 K | $516 K | $324 K | $1 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Tenax Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 5 · Material agreement 3 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2024 | $100 M | Private placement after listing | $50 to $250 million | 24 | equity, options | SEC |
| May 2022 | $8 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| Jul 2021 | $10 M | Private placement after listing | $10 to $50 million | 1 | options | SEC |
| Jul 2020 | $5 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| Nov 2013 | $7 M | Private placement after listing | $2 to $10 million | 4 | equity | SEC |
| Aug 2013 | $5 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Feb 2013 | $2 M | Private placement after listing | $2 to $10 million | 2 | equity, options | SEC |
| Jun 2009 | $5 M | No. 1 | $2 to $10 million | 2 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Tenax Therapeutics, Inc. compares in Biotechnology
- Market cap$86 M · higher than 33% of 726
- Revenue growth-68.8% · higher than 11% of 438
- Price / book0.9× · lower than 82% of 534
- FCF yield-13.3% · higher than 51% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Tenax Therapeutics, Inc.🇺🇸 | $86 M | — | — | -68.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Tenax Therapeutics, Inc.? Verify and update this profile — free
Show Tenax Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.